We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-0.1%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$2.83B
AUM Growth
-$798M
Cap. Flow
-$482M
Cap. Flow %
-17.04%
Top 10 Hldgs %
54.55%
Holding
115
New
16
Increased
15
Reduced
28
Closed
28

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$101M
2
BBNX
Beta Bionics
BBNX
+$29.7M
3
INSM icon
Insmed
INSM
+$27.9M
4
DYN icon
Dyne Therapeutics
DYN
+$25.3M
5
SLDB icon
Solid Biosciences
SLDB
+$21.4M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$80.9M
2
NUVL
Nuvalent
NUVL
+$77.1M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$62.8M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$62.6M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$54.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEN icon
101
Penumbra
PEN
$12.6B
– –
-73,338
Closed -$17.4M
PEPG icon
102
PepGen
PEPG
$118M
– –
-829,536
Closed -$3.14M
PRAX icon
103
CALL
Praxis Precision Medicines
PRAX
$8.11B
– –
-500,000
Closed -$38.5M
PRCT icon
104
Procept Biorobotics
PRCT
$1.02B
– –
-290,659
Closed -$23.4M
PYXS icon
105
Pyxis Oncology
PYXS
$185M
– –
-188,462
Closed -$294K
TARS icon
106
Tarsus Pharmaceuticals
TARS
$2.55B
– –
-186,662
Closed -$10.3M
TRIB
107
Trinity Biotech
TRIB
$8.9M
– –
-59,667
Closed -$1.58M
VERU icon
108
Veru
VERU
$35.5M
– –
-648,316
Closed -$4.22M
VRCA icon
109
Verrica Pharmaceuticals
VRCA
$89M
– –
-324,967
Closed -$2.27M
RAPP
110
Rapport Therapeutics
RAPP
$1.96B
– –
-311,551
Closed -$5.53M
ORKA
111
Oruka Therapeutics
ORKA
$5.31B
– –
-845,567
Closed -$16.4M
ZBIO
112
Zenas BioPharma
ZBIO
$1.96B
– –
-744,035
Closed -$6.09M
CBLL
113
CeriBell Inc
CBLL
$673M
– –
-180,546
Closed -$4.67M
SEPN
114
Septerna Inc
SEPN
$1.51B
– –
-750,000
Closed -$17.2M
NARI
115
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-178,797
Closed -$9.13M
1 2 3 4
5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Perceptive Advisors held 115 positions worth $2.83B, down 22% from $3.63B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Perceptive Advisors withdrew a net $482M in Q1 2025, closing 28 positions and reducing 28 holdings. Its most notable exit was Procept Biorobotics, an estimated $23.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Beta Bionics worth $19.5M.

  • Perceptive Advisors's largest Q1 2025 buy was Beta Bionics: 1,593,608 shares worth $19.5M.
  • Perceptive Advisors added most to Edgewise Therapeutics in Q1 2025, an estimated $101M increase.
  • Perceptive Advisors's biggest Q1 2025 reduction was Vaxcyte, cutting an estimated $80.9M.
  • Perceptive Advisors fully exited Procept Biorobotics in Q1 2025, selling an estimated $23.4M.
  • Perceptive Advisors's ten largest holdings make up 55% of its $2.83B portfolio in Q1 2025.
  • Perceptive Advisors opened 16 new positions and closed 28 in Q1 2025.
  • Perceptive Advisors's portfolio value fell 22% quarter-over-quarter to $2.83B.

Based on Perceptive Advisors's 13F filing for Q1 2025, filed 15 May 2025.